Navigation Links
Bionovo Reports Third Quarter 2008 Financial Results
Date:11/3/2008

al dryness,

over other treatments. The Company expects to begin human clinical

trials for VG101 late in 2008 or early in 2009.

"The third quarter of the year continued the positive scientific progress for Bionovo," said Dr. Isaac Cohen, O.M.D., Bionovo's Chairman and Chief Executive Officer. "After much preparation and discussion with the FDA and our advisors, we are now poised to begin the next phase of clinical testing for our portfolio of women's health and oncology drug candidates. We are also continuing promising discussions with potential pharmaceutical partners."

"With over seventeen million dollars in cash, cash equivalents and short- term investments, and a lower than industry clinical trial cost profile, we are poised to progress our lead drug candidates through these challenging economic times," added Tom Chesterman, Bionovo's Senior Vice President and Chief Financial Officer. "Given our current plans and expectations, this funding will be sufficient for at least the next 12 months"

A full financial report on Form 10-Q is expected to be filed by Tuesday, November 4, 2008.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.b
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
2. Bionovo Announces Proposed Public Offering of Common Stock
3. Bionovo to Present at the Biotechnology Industry Organization (BIO) Investor Forum
4. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
5. Bionovo Announces Third Quarter 2007 Financial Results
6. Bionovo to Present at Bank of Montreals 2007 Focus on Healthcare Conference
7. George Butler Joins Bionovos Board of Directors
8. Louis Drapeau Joins Bionovos Board of Directors
9. Bionovo Identifies and Describes ER-beta Selective Compounds for the Treatment of Vaginal Dryness
10. Bionovo to Present Recent Findings of BN107 and BN108, Its Anticancer Agents, at the American Association of Cancer Research
11. Bionovo Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Weighing applications in pharmaceutical ... final product. However, while the pharmaceutical industry is ... as Good Manufacturing Practices (GMP) usually provide only ... manufacturer to interpret these guidelines and assess process ... METTLER TOLEDO experts have created a new white ...
(Date:10/1/2014)... -- Pfanstiehl has announced the launch of cGMP-produced, ... USA under ICH Q7 ... playing a key role in protein glycosylation.  Now, ... media supplementation with mannose can improve overall culture ... Dr. Christopher Wilcox , VP, Business Development ...
(Date:10/1/2014)... The participants committed to not only ... their own time adjusting, tweaking and testing virtual models ... ready for judging. , “I enjoyed being involved as ... “The entries showed a commendable range exploring the ... the print medium and the creativity of the contestants.” ...
(Date:10/1/2014)... September 30, 2014 In response ... tools to address sales, training and consumer engagement ... developed innovative mobile applications to turn their clients’ ... agency’s latest customized mobile app creations, are now ... , In partnership with Toyota, StudioPMG created a ...
Breaking Biology Technology:Comply with Weighing-Related Regulations in Pharma Manufacturing 2Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Array Architects Challenges Staff to Create with 3D Printer 2Digital Agency Studio PMG Launches New Case Studies on Website 2
... NEW YORK, Jan. 7 Aisling Capital announced today ... its newest life sciences fund, Aisling Capital III, LP. ... companies developing pharmaceutical, biopharmaceutical and medical products, as well ... other important services to the healthcare industry. With a ...
... 7 Codexis, Inc. today announced,a licensing agreement with ... product, using a proprietary Codexis,biocatalyst. Teva, the largest ... of this generic product. The product is one ... States. , Under the agreement, ...
... , - Most Comprehensive ... Ansell Healthcare, a global leader in barrier ... showcasing the most recent offerings at,the Arab Health fair ... 6 Booth E10).,Ansell invites healthcare workers to discover its ...
Cached Biology Technology:Aisling Capital Announces Close of US$650M Life Sciences Fund 2Codexis, Teva in Licensing Agreement Final 2Managing Risk Through Quality: Ansell Healthcare's Innovative Gammex(R) Glove Range on Display at Arab Health 2009 2
(Date:9/30/2014)... New England Journal of Medicine reports positive results ... crizotinib against the subset of lung cancer marked by ... of 50 patients with advanced non-small cell lung cancer ... was 72 percent, with 3 complete responses and 33 ... takes for the disease to resume its growth after ...
(Date:9/30/2014)... involving mice and published in the October 2014 issue ... , suggests that just because you can do it, ... of Italian scientists have found that using marijuana in ... system. This damage may result in autoimmune diseases and ... disease and rheumatoid arthritis in adulthood. , "I hope ...
(Date:9/30/2014)... is available in German . ... behavioural response to risky situations such as exposure to ... now found in a long-term study on different populations ... metabolic rate and ambient temperature. High metabolic rates and ... in these scenarios birds were more likely to approach ...
Breaking Biology News(10 mins):NEJM: Crizotinib effective in Phase 1 trial against ROS1 lung cancer 2Adolescent exposure to thc may cause immune systems to go up in smoke 2Risky metabolism 2
... Science University (OHSU) and Intel Corp. are teaming ... the field of personalized medicine by dramatically increasing ... patient,s individual genetic profile. Through a multi-year research ... from the two institutions will develop hardware, software ...
... new tool to search for more effective medications and new ... catalogue the entire set of lightweight, carbon-containing molecules that chemists ... has more than 10^60 (that,s 1 with 60 zeroes after ... of the world,s problems have molecular solutions in this chemical ...
... today, a special issue of the Philosophical Transactions ... a major challenge facing our society: feeding a global ... capita food consumption, while preventing widespread ecological and social ... Scientist at The Woods Hole Research Center (WHRC) and ...
Cached Biology News:OHSU teams with Intel to decode the root causes of cancer and other complex diseases 2OHSU teams with Intel to decode the root causes of cancer and other complex diseases 3OHSU teams with Intel to decode the root causes of cancer and other complex diseases 4OHSU teams with Intel to decode the root causes of cancer and other complex diseases 5Scientists map all possible drug-like chemical compounds 2Scientists map all possible drug-like chemical compounds 3Ecology, economy and management of an agro-industrial Amazon frontier 2Ecology, economy and management of an agro-industrial Amazon frontier 3
... plus software to note when an animal is ... and trigger a penaltyThe Spatial Behavior line is ... video camera, frame grabber, and feature extraction software ... and up to 6 moving animals. Software ...
... Magnetofection technology, SilenceMag is the most ... rapid and easy to use, SilenceMag ... Specifically designed for siRNA delivery, SilenceMag ... low doses of siRNA.,SilenceMag formulation gives ...
Denhardt's Solution is a mixture of blocking agents used in membrane-based hybridization protocols. The solution contains 1% Ficoll (type 400) 1% polyvinylpyrrolidone and 1% bovine serum albumin. Ste...
... system from Molecular Devices provides precise dispensing ... The system handles a variety of plate ... and 1536-welland is the first to handle ... optimized to dispense from four different channels ...
Biology Products: